Venbio Global Strategic
SelectiveSan Francisco, CABiotechnology, Pharmaceuticals, HealthcareLast fund filed June 2024
6 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| venBio Global Strategic Fund V | June 2024 | Indefinite | $505M | 162 |
| venBio Global Strategic Fund IV | April 2021 | $550M | $550M | 147 |
| venBio Global Strategic Fund III | June 2018 | $386M | $386M | 100 |
| venBio Global Strategic Fund II | March 2015 | $337M | $337M | 31 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
8 partners are named across this firm’s filings, 6 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Aaron Royston | Selective | Biotech & pharma, Medical devices | 11 | 2 |
Classified sectors of Venbio Global Strategic’s own portfolio companies, based on 23 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Venbio Global Strategic’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Venbio Select | 16 | Alexo Therapeutics, Apellis Pharmaceuticals, Attralus, Axonis Therapeutics, Cerus Endovascular, Checkmate Pharmaceuticals, FOG PHARMACEUTICALS, INSAMO, LIMERICK BIOPHARMA, Metacrine, Mirna Therapeutics, NFlection Therapeutics, PRECISION BIOSCIENCES, Solstice Biologics, Tallac Therapeutics, TP Therapeutics |
| Sofinnova Venture Partners | 5 | Aeovian Pharmaceuticals, Apellis Pharmaceuticals, Checkmate Pharmaceuticals, Marea Therapeutics, RayzeBio |
| Vivo Innovation | 3 |
| Antoinette Delhonte | Quiet | None listed | 0 | 0 |
| Corey Goodman | Quiet | Biotech & pharma | 11 | 0 |
| David Pezeshki | Quiet | None listed | 1 | 0 |
| Paul BrookeNot on the current fund | Quiet | None listed | 1 | 0 |
| Richard Gaster | Quiet | Biotech & pharma | 8 | 0 |
| Robert AdelmanNot on the current fund | Quiet | Biotech & pharma | 5 | 0 |
| Yvonne Yamanaka | Quiet | Biotech & pharma | 3 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| Harmony Biosciences II, Menlo Therapeutics, TP Therapeutics |
| Westlake Biopartners | 3 | Arpeggio Biosciences, IMPEL NEUROPHARMA, Neurogastrx |
| Atlas Venture | 2 | Akero Therapeutics, Caldera Therapeutics |
| Orbimed Asia Partners | 2 | ImmPACT Bio USA, TP Therapeutics |
| Orbimed Genesis | 2 | ImmPACT Bio USA, TP Therapeutics |
| 270 Healthcare Growth | 1 | Swift Health Systems |
| Aisling Capital | 1 | Elevation Oncology |
| ARCH Venture Partners | 1 | Metacrine |
| Caduceus Capital | 1 | TP Therapeutics |
| Clarus | 1 | Eyconis |
| Lightstone Singapore | 1 | Tallac Therapeutics |
| Lightstone Ventures | 1 | Tallac Therapeutics |
| Nextech Viii Carry Scsp | 1 | Arrakis Therapeutics |
A shared board seat: a company where filings name a Venbio Global Strategic partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.